Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

BACKGROUND: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. Here, we explored the predictive and pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chrisanthar, Ranjan, Knappskog, Stian, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Skjønsberg, Gudbrand, Aas, Turid, Schlichting, Ellen, Fjösne, Hans E., Nysted, Arne, Lillehaug, Johan Richard, Lønning, Per Eystein
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083424/
https://www.ncbi.nlm.nih.gov/pubmed/21556366
http://dx.doi.org/10.1371/journal.pone.0019249

Ejemplares similares

Ejemplares similares